Chooper's Guide ... the Internet's most comprehensive substance abuse treatment, prevention and intervention resource directory.

Lavita RDS

Phone Number

view phone(858) 442 3106


1878 West 12600 South Riverton, Utah, United States 84065



» Leave Testimonial


The LaVita RDS Story In 1982 Dr. Kenneth Blum began his groundbreaking study of addictive behaviors and genetic connections. He and a partner were the first to discover the human gene linked to addictive activities. His vast wealth of research and a deep desire to help others lead him to the creation of a nutraceutical Dopamine agonist formula that is now protected by two US patents and one EU patent. He discovered that many people are lacking in healthy Dopamine levels which may contribute to feelings of depression, low energy and a desire to augment dopamine through risk taking behaviors. Synaptamine™ from LaVita RDS is Dr. Blum’s licensed formula delivered through revolutionary Nano sizing technology. 


How Synaptamine Works


As addiction professionals, we are becoming increasingly concerned about preteenagers and young adults' involvement with substance abuse as a way of relieving stress and anger. The turbulent underdeveloped central nervous system, especially in the prefrontal cortex (PFC), provides impetus to not only continue important neuroimaging studies in both human and animal models, but also to encourage preventive measures and cautions embraced by governmental and social media outlets. It is well known that before people reach their 20s, PFC development is undergoing significant changes and, as such, hijacks appropriate decision making in this population. We are further proposing that early genetic testing for addiction risk alleles will offer important information that could potentially be utilized by their parents and caregivers prior to use of psychoactive drugs by these youth. Understandably, family history, parenting styles, and attachment may be modified by various reward genes, including the known bonding substances oxytocin/vasopressin, which effect dopaminergic function. Well-characterized neuroimaging studies continue to reflect region-specific differential responses to drugs and food (including other non-substance-addictive behaviors) via either "surfeit" or "deficit." With this in mind, we hereby propose a "reward deficiency solution system" that combines early genetic risk diagnosis, medical monitoring, and nutrigenomic dopamine agonist modalities to combat this significant global dilemma that is preventing our youth from leading normal productive lives, which will in turn make them happier.



For the full article go to: The Addictive Brain: All Roads Lead to Dopamine


The Addiction Gene: Why Millions are Inherently at Risk

Can you imagine jumping out of a plane without a Parachute? In regards with addictions many do, why?

Addiction is a global and widespread problem in today’s society. In 2008, Americans aged 18-24 had the highest rate of alcohol use disorder… and drug use disorder… Men are more likely than women to have problems with alcohol or drugs. 2007 saw 182 million prescriptions written for pain medications. As our late US president has stated many times “Just Say NO” should be the logical answer to this addiction problem.


Through the conviction that drug and alcohol dependence was a DISEASE rather than a Symptom of Moral Weakness was growing in the late nineteenth and early twentieth century, there was no knowledge of how the disease might be acquired or treated.

The good news is the acceptance of “Reward Deficiency Syndrome” (RDS) as an umbrella term for a predisposition to obsessive, compulsive and impulsive behaviors that are associated with genetic differences that can lead to addiction, paves the way to defining addiction as a brain disorder involving impairments in so called “Reward Circuitry.” This definition of addiction has now been adopted by the American Society of Addiction Medicine (ASAM) and DMS-5, and is a realization that paved the way for changes and advancements in treatment options.

1. Serotonin the hypothalamus indirectly activates opiate receptors and causes a release of Enkephalins in the ventral tegmental region A - The Enkephains inhibit the firing of GABA which originates in the substantia nigra A-region;

2. GABA normal  role is to inhibit and control the amount of dopamine released at  the ventral tegmentol regions for action at the nucleus accumbens. When the Dopamine is released in the nucleus accumbens it activates Dopamine 02 receptors, a key reward site. This releaseis also regulated by Enkephalins acting through GABA. The supply of Enkephallns is controlled by the amount of the neu­ropeptidases, which destroy them.

3. Dopamine may also be released info the amygdala. From the amygdalo,dopa­ mine reaches the hippocampus and the CA, cluster cells stfmulates dopamine D2 receptors,another reward site.

4. An alternate pathway involves norepinephrine in the locus of ceruleus whose fibers project into the hippocampus at a reward area centering around cluster cells which have not been precisely identified, but which have been designated     as CAx. When GABAA receptors in the hippocampus are stimulated, they cause the release of norepinephrine at the CAx site. It is to be noted that the glucose receptor (GR) in the hypothalamus is intricately involved and "'links" the seroto­   nergic system with opioid peptides leading to the ultirmate release of dopamine   at the n.accumbens.



Once it was true, all roads lead to Rome. This simple truth is not too dissimilar from the reward circuitry of the brains of Homo Sapiens. Numerous experiments have established that the brain’s major reward neurotransmitter pathway, the road to Rome, is indeed Dopamine. Reward circuitry, the cascade of neurotransmission in the brain that leads to the release of Dopamine, is kicked off by any pleasurable experience. Everything from Eating, the having Sex and even Skydiving can get it going. The point of the reward circuitry is to positively reinforce actions that promote the survival of the species. During what the brain perceives to be beneficial actions, Dopamine’s release makes out brains “happy,” thus encouraging us to do it again.


Given that about 30% of us are born with genetically induced Low Dopamine brain function how can we overcome this survival variant of human nature and prevent excessive craving behavior?... Mark Gold, chairmen of the Department of Psychiatry at the University of Florida, College of Medicine in Gainesville, accurately stated, “In spite of all the effort and progress made by the addiction community, as a whole it has failed to both comprehend and willingly incorporate well established, evidence-based medical modalities into treatment, especially as it relates to relapse prevention.” I am encouraged that for the first time in this millennium the addiction community is prepared to embrace newer scientific and clinically proven modalities. In this regard, the following areas must be adequately addressed by treatment providers going forward:

  • Genetic testing to determine risk for RDS
  • Safe and Effective non-addictive Dopamine Agonist known as Synaptamine (KB220Z) to activate Dopaminergic pathways in the brain…

To date, the bottleneck is that typical pharmaceutical agents that have activation qualities are too powerful and have profound contraindications and side-effects. The good news is that the Dopaminergic system can be safely & effectively stimulated with a patented natural, non-addictive Dopamine Agonist known as Synaptamine (KB220Z). Neuroimaging tools such as (qEEG, fMRI and PET) have been used to demonstrate the impact and effectiveness of Synaptamine as a safe activator of brain reward Dopamine… (See La Vita Studies)

Ultimately, it should have benefits in the form of craving reduction, prevention of relapse, and quite possibly prevention of all RDS behaviors, especially in adolescents…


Finally, it should be stated just because you have a genetic predisposition does not mean you will automatically become an addict... As Steven Susman of the University of southern California points out, rather than being a victim to our genetic factors based on our DNA, RDS is highly impacted by environmental (epigenetic) factors affecting our RNA… The take home message is one is not doomed because of their genes to become addict, but definitely at high risk. This is why Synaptamine was invented so that a compound could possible reduce the cravings associated with RDS and other environmental and behavioral tool can be implemented so these genes are not activated or woken up.


Additional Resources

Volume 1 Link:
Full Article Link:




Synaptamine™ 30 Fl Oz Bottle

Synaptamine™ uses a patented KB220z Neuroadaptagen technology that is nano sized providing greatly accelerated absorption by the body for optimal brain health, enhanced energy, reduced stress as well as helping nutritional maintenance of overall mood health and a sense of well-being.

Our Synaptamine™ Patented Formula is made of a proprietary blend containing: Pyridoxal-5-Phos USP, L-Tyrosine, L-Glutamine, Rhodiola Rosea Root SE, Rosavins, Griffonia Seed Extract 5-HTP, L Phenylalanine, Chromium GTF Plus, Passion Flower SE Isovitexin, N-Acetyl-L-Cysteine USP, Glucosamine N-Acetyl, Arabinogalactan FiberAid AG99, Aloe Vera FD Powder 200X, White Birch Bark 4:1 Extract, Boswellia Serrata Gum Extract, Spirulina Algae. To obtain a patent, very thorough research and testing was required. For a more in depth look at our science supporting our claims please refer to our patent:

Product Description

Synaptamine™ 30 Fl Oz Bottle Synaptamine™ uses a patented KB220z Neuroadaptagen technology that is nano sized providing greatly accelerated absorption by the body for optimal brain health, enhanced energy, reduced stress as well as helping nutritional maintenance of overall mood health and a sense of well-being.